1 |
Peinemann F, Grouven U, Kroger N, Pittler M, Zschorlich B, Lange S. Unrelated donor stem cell transplantation in acquired severe aplastic anemia: a systematic review. Haematologica 2009;94:1732-42.
DOI
|
2 |
Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med 2006;354:1813-26.
DOI
|
3 |
Bacigalupo A. Guidelines for the treatment of severe aplastic anemia. Working Party on Severe Aplastic Anemia (WPSAA) of the European Group of Bone Marrow Transplantation(EBMT). Haematologica 1994;79:438-44.
|
4 |
Young NS, Barrett AJ. The treatment of severe acquired aplastic anemia. Blood 1995;85:3367-77.
DOI
|
5 |
Charbonnier A, Sainty D, Faucher C, Arnoulet C, Chabannon C, Blaise D. Immune reconstitution after blood cell transplantation. Hematol Cell Ther 1997;39:261-4.
DOI
|
6 |
Bittencourt H, Rocha V, Chevret S, Socie G, Esperou H, Devergie A, et al. Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation. Blood 2002;99:2726-33.
DOI
|
7 |
Singhal S, Powles R, Treleaven J, Kulkarni S, Sirohi B, Horton C, et al. A low CD34+ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 x 10(6) CD34+ cells/kg be considered the minimum threshold? Bone Marrow Transplant 2000;26:489-96.
DOI
|
8 |
Bacigalupo A. How I treat acquired aplastic anemia. Blood 2017;129:1428-36.
DOI
|
9 |
Barone A, Lucarelli A, Onofrillo D, Verzegnassi F, Bonanomi S, Cesaro S, et al. Diagnosis and management of acquired aplastic anemia in childhood. Guidelines from the Marrow Failure Study Group of the Pediatric Haemato-Oncology Italian Association (AIEOP). Blood Cells Mol Dis 2015;55:40-7.
DOI
|
10 |
Killick SB, Bown N, Cavenagh J, Dokal I, Foukaneli T, Hill A, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol 2016;172:187-207.
DOI
|
11 |
Islam MS, Anoop P, Datta-Nemdharry P, Sage D, Gordon-Smith EC, Turner D, et al. Implications of CD34+ cell dose on clinical and haematological outcome of allo-SCT for acquired aplastic anaemia. Bone Marrow Transplant 2010;45:886-94.
DOI
|
12 |
Perez-Simon JA, Caballero MD, Corral M, Nieto MJ, Orfao A, Vazquez L, et al. Minimal number of circulating CD34+ cells to ensure successful leukapheresis and engraftment in autologous peripheral blood progenitor cell transplantation. Transfusion 1998;38:385-91.
DOI
|
13 |
Perez-Simon JA, Diez-Campelo M, Martino R, Sureda A, Caballero D, Canizo C, et al. Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation. Blood 2003;102:1108-13.
DOI
|
14 |
Le Blanc K, Samuelsson H, Gustafsson B, Remberger M, Sundberg B, Arvidson J, et al. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 2007;21:1733-8.
DOI
|
15 |
de la Rubia J, Cantero S, Sanz GF, Remigia MJ, Monteagudo E, Moscardo F, et al. Transplantation of CD34+ selected peripheral blood to HLA-identical sibling patients with aplastic anaemia: results from a single institution. Bone Marrow Transplant 2005;36:325-9.
DOI
|